Bio-Thera Solutions announced that a phase 3 clinical trial comparing the efficacy and safety of its bevacizumab biosimilar, BAT1706, to the reference product (Avastin), returned positive top-line results.
Bio-Thera Solutions announced that a phase 3 clinical trial comparing the efficacy and safety of its bevacizumab biosimilar, BAT1706, to the reference product (Avastin) returned positive top-line results.
The Chinese commercial-stage biopharmaceutical company said in a press release that BAT1706 proved equivalent to bevacizumab in overall response rate as a first-line treatment for non-squamous non-small cell lung cancer.
“We are pleased to report on our second proposed biosimilar with positive study results,” said Shenfeng Li, PhD, the chief executive officer of Bio-Thera Solutions. “These results demonstrate the potential of our proposed bevacizumab biosimilar to be a safe and effective treatment option for cancer patients. Bio-Thera is committed to increasing patient access to innovative medicines through the development of high-quality biosimilars.”
Avastin is indicated in the US to treat metastatic colorectal cancer, non-squamous non-small cell lung cancer, persistent, recurrent, or metastatic cervical cancer, and epithelial ovarian, fallopian tube, or primary peritoneal cancer, along with other conditions.
According to the press release, “BAT1706 works by binding the vascular endothelial growth factor (VEGF) protein.” It has not yet received regulatory approval in any country.
The trial consisted of a multicenter, randomized, double-blind study which evaluated the pharmacokinetics and immunogenicity of BAT1706. Results of the study have yet to be released and the company is developing several other proposed biosimilars including ustekinumab, secukinumab and golimumab.
Separately this week, the FDA requested data for Formycon’s Lucentis biosimilar candidate FYB201, as part of a review process for a biologics license application (BLA). The company stated it will take around 4 months to generate the additional data. However, Bioeq, its licensing partner, announced it would withdraw its BLA for the biosimilar candidate, provide requested data, and resubmit the application after, which may delay approval of the BLA.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Annual STADA Report Shows Record Profit Growth for 2023
March 25th 2024Germany-based biosimilar manufacturer STADA Arzneimittel reports strong financial performance in 2023 with double digit sales growth and billions in profits. The CEO credits the company’s success on their strong company culture and focus for innovation.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.